CAR-T Cell Therapy for Advanced Solid Tumors
Part of Cancer clinical trials.
This trial tests IMC001, a new type of immune cell therapy designed to fight advanced solid cancers that have stopped responding to standard treatments. The therapy uses your own immune cells engineered to recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid cancer (like gastric, breast, ovarian, colorectal, pancreatic, or biliary cancer) that has grown despite previous treatments
- Your cancer cells must test positive for a marker called EpCAM (a protein found on certain cancer cells)
- You've already tried at least two standard cancer treatments without success or couldn't tolerate them
- Your overall health is good enough (ECOG score 0–1: able to carry out normal activities with minimal limitations)
- Your blood counts and organ function (liver, kidney, heart, lungs) are within acceptable ranges
- You're between 18 and 75 years old
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy made from your own immune cells to treat advanced cancers that have not responded to other treatments. It may be an option if your tumor has a specific target and you are otherwise healthy enough.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a new type of immune cell therapy (NKG2D CAR-T cells) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if these specially engineered cells can shrink tumors or slow their growth.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests a new treatment called Anti-CEA-CAR-T cells, which are specially modified immune cells that target a protein called CEA found on certain cancer cells. It is for people with advanced solid tumors, especially digestive system cancers, that have not responded to other treatments.
Hear when a new Epithelial Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.